Skip to main content
Home

Language & Country Selector for Desktop

language-selector-globe Canada | en

Choose location

language-selector-globe Canada |
EnglishFrançais
  • Americas
  • Asia Pacific
  • Europe
  • International
  • Middle East & Africa
Argentina | es
Brazil | pt
Canada | en
Canada | fr
Central America | es
Colombia | es
Mexico | es
United States | en
Venezuela | es
Australia | en
Bangladesh | en
Hong Kong S.A.R. | zh
India | en
Indonesia | en
Japan | ja
Korea | ko
Mainland China | zh
Malaysia | en
Pakistan | en
Philippines | en
Singapore | en
Taiwan | zh
Austria | de
Belgium | fr
Belgium | nl
Bulgaria | bg
Czech Republic | cs
Czech Republic | en
Denmark | da
Estonia | et
Finland | fi
France | fr
Germany | de
Greece | el
Hungary | hu
Ireland | en
Italy | it
Latvia | lv
Lithuania | lt
Netherlands | nl
Norway | no
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Serbia | sr
Slovakia | sk
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
United Kingdom | en
Global | en
Novartis Foundation | en
Sandoz | en
Egypt | en
Israel | he
South Africa | en
Turkey | tr

Language & Country Selector for Mobile

language-selector-globe Canada

Choose location

language-selector-globeCanada
EnglishFrançais
Americas Asia Pacific Europe International Middle East & Africa
Argentina | es
Australia | en
Austria | de
Bangladesh | en
Belgium | fr
Belgium | nl
Brazil | pt
Bulgaria | bg
Canada | en
Canada | fr
Central America | es
Colombia | es
Czech Republic | cs
Czech Republic | en
Denmark | da
Egypt | en
Estonia | et
Finland | fi
France | fr
Germany | de
Global | en
Greece | el
Hong Kong S.A.R. | zh
Hungary | hu
India | en
Indonesia | en
Ireland | en
Israel | he
Italy | it
Japan | ja
Korea | ko
Latvia | lv
Lithuania | lt
Mainland China | zh
Malaysia | en
Mexico | es
Netherlands | nl
Norway | no
Novartis Foundation | en
Pakistan | en
Philippines | en
Poland | pl
Portugal | pt
Romania | ro
Russia | ru
Sandoz | en
Serbia | sr
Singapore | en
Slovakia | sk
South Africa | en
Spain | es
Sweden | sv
Switzerland | de
Switzerland | fr
Taiwan | zh
Turkey | tr
United Kingdom | en
United States | en
Venezuela | es
    • About 
      • Novartis in Canada 
        • Novartis Biome in Canada 
      • Strategy 
      • Diversity and Inclusion 
      • People and Culture 
      • Products 
      • Canadian Leadership Team 
      • Contact 
        • Email Us 
        • For Consumers 
        • General contact 
        • Canadian Locations 
      About Novartis Canada About
    • Patients and Caregivers 
      • The Novartis Commitment to Patients and Caregivers 
      • Adverse Event Reporting 
      • Grants and Donations 
      Patients and Caregivers Patients and Caregivers
    • Healthcare Professionals 
      • HCP Portal 
      • Products 
      • Pipeline (EN) 
      • Adverse Event Reporting 
      • Novartis Clinical Trials 
      • Disclosure Of Payments To Healthcare Professionals 
      Healthcare Professionals Header Image Healthcare Professionals
    • ESG 
      • Ethical Behavior 
        • Code of Ethics 
        • SpeakUp 
      • Grants and Donations 
      • Corporate Responsibility 
        • AODA Compliant - EN (PDF 0.2 MB) 
        • AODA Compliant - FR (PDF 0.2 MB) 
        • AMA Compliant - EN (PDF 0.2 MB) 
        • AMA Compliant - FR (PDF 0.2 MB)  
        • Disclosure Of Payments To Healthcare Professionals 
        • Environmental Sustainability 
      ESG Header ESG
    • Careers 
      • Diversity & Inclusion 
      • People and Culture 
      • Career Search 
      • How We Work 
      • Well-being 
      Careers Header Careers
    • Coronavirus 
      coronavirus-microscope-image Coronavirus
    About Novartis Canada Home
Header
News

News

News and more from the frontiers of medicine

Previous Next

Media inquiry

For Journalists with a media inquiry, please contact us:


Novartis Pharmaceuticals Canada Inc.
Department of Communications
385 Bouchard Blvd.
Dorval, Quebec H9S 1A9

Phone: (514) 633-7873

Media Releases

Media Releases

Media releases are intended for journalists, investors, and shareholders.

Stories

Stories

Our research redefines the way we understand disease and develop medicines. Discover the people and stories that make it possible.

09 Jun 2023 08:26:00 [email protected]

Novartis global survey results show #ChronicMyeloidLeukemia is not yet solved, highlighting the need for greater patient voice in treatment decisions at #EHA2023 #NovartisNews

Previous Next

Novartis Canada

Navigate Novartis
  • Patients & Caregivers
  • Healthcare Professionals
  • ESG
  • Careers
Media Center
  • News Archive
Our Portfolio
  • Novartis Clinical Pipeline
  • Novartis Product Portfolio
Other Novartis Websites
  • Global site
  • Sandoz Canada
Footer Bottom
© 2023 Novartis AG
  • Terms of Use
  • Privacy Policy
  • Web Accessibility
  • Cookie Settings
  • Site Map
Novartis Site Directory
This site is intended for an audience in Canada.